A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX)

Core Insights - ImmunityBio (IBRX) reported a 3Q25 GAAP EPS loss of -$0.07, beating estimates by approximately $0.04 [1] - Revenue for the quarter was $32.06 million, representing a significant year-over-year increase of 425% and slightly exceeding expectations by $0.18 million [1] Financial Performance - The company achieved a GAAP EPS loss of -$0.07, which is an improvement over analyst expectations [1] - Revenue reached $32.06 million, marking a 425% increase compared to the same quarter last year [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, focusing on biotechnology companies with innovative therapies [1] - The approach combines scientific expertise with financial analysis to evaluate drug candidates and market opportunities [1]